Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a&nbsp;head-to-head&nbsp;comparison of the Pre-AndroCoV Trial. (Brazil, 2020-10-30) 3-arm no-control trial of 585 PCR+ patients RESULTS

TrumpLyftAlles | 5 points | Oct 30 2020 23:56:08

https://www.researchsquare.com/article/rs-98106/v1

[-] TrumpLyftAlles | 2 points | Oct 30 2020 23:57:33

Covid19Crusher's tweet letting me know about this study:

Brazilian 3-arm randomized no-control trial compares hydroxychloroquine / nitazoxanide / ivermectin in early treatment of 585 RT-PCR confirmed COVID outpatients. Not 1 hospitalization compared to a 16% case average nationally. Odds ratio: 0.000000. Hmm.

A few more points:
Time to treat 3 days but time from symptom onset
HCQ / NTZ / IVM equally efficacious. Hmm.
ca. 80% of patient with vitamin D supplementation
ca. 50% under spironolactone
ca. 20% with vitamin C and/or Zinc
Hmm. Amazing...
Too good to be true?

That trial was not even the primary scientific objective of the authors who pursue an interesting androgenic treatment angle and wanted to select the best of the 3 studied drugs for a further RCT, called AndroCoV. Have they already solved Covid-19?

https://www.firstwordpharma.com/node/1735447?tsid=17

[Not C19C] Were the people actually sick? Did they do viral cultures to confirm? There’s a 95% asymptomatic rate pretty much everywhere now. When you account for presymptomatic you still get an awful lot of PCR positives that aren’t actually sick.

C19C:

87% symptomatic

[Not C19C]

In the other hand, similar results to Dr. Brian Tyson. 3 days on symptoms onset is very early, could that have contributed to the efficacy? And no doubt the 80% vitamin D is another positive advantage. Too good to be true, but not imposible.

Thanks C19C!